Year | Method* | MDR-TB cases tested for second-line drug resistance | XDR cases among MDR-TB cases tested | Proportion of MDR cases that were XDR (percent) | |
Armenia | 2007 | Survey | 199 | 8 | 4 (1.8-7.8) |
Azerbaijan, Baku | 2007 | Survey | 431 | 55 | 12.8 (9.8-16.3) |
Bangladesh¶Δ | 2008 | Surveillance | 168 | 1 | 0.6 |
China¶ | 2008 | Survey | 270 | 30 | 11.1 (7.6-15.5) |
Estonia | 2008 | Surveillance | 72 | 9 | 12.5 |
Georgia | 2006 | Survey | 70 | 3 | 4.3 (0.9-12) |
India, Gujarat state¶ | 2006 | Survey | 216 | 7 | 3.2 (1.2-6.6) |
Kazakhstan | 2008 | Surveillance | 373 | 16 | 4.3 |
Latvia | 2008 | Surveillance | 128 | 19 | 14.8 |
Lithuania | 2003 to 2006 | Surveillance | 173 | 25 | 14.5 |
Moldova | 2006 | Survey | 47 | 3 | 6.4 (1.3-17.5) |
Russia, Tomsk oblast¶ | 2003 to 2005 | Surveillance | 458 | 30 | 6.6 |
South Africa¶ | 2008 | Surveillance | 5451 | 573 | 10.5 |
Tajikistan, Dushanbe and Rudaki | 2009 | Survey | 100 | 21 | 21 (13.5-30.3) |
Ukraine, Donetsk oblast | 2006 | Survey | 20 | 3 | 15 (3.2-37.9) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟